摘要
【目的】探讨安罗替尼治疗晚期非小细胞肺癌(NSCLC)患者的疗效及对患者生活质量的影响。【方法】选取2022年8月至2024年8月在本院诊治的98例晚期NSCLC患者,按治疗方法不同分为对照组(给予常规化疗)和观察组(在常规化疗的基础上给予安罗替尼治疗),每组49例。比较两组临床疗效、血清指标、生活质量及不良反应发生率。【结果】观察组疾病控制率、总体有效率高于对照组(P<0.05)。治疗后,观察组血管内皮生长因子(VEGF)、糖类抗原125(CA125)、基质金属蛋白酶-9(MMP-9)水平均低于对照组(P<0.05);治疗后,观察组生活质量综合评定问卷(GQOLI-74)评分高于对照组(P<0.05)。观察组不良反应总发生率与对照组比较,差异无统计学意义(P>0.05)。【结论】安罗替尼联合常规化疗治疗晚期NSCLC患者的疗效显著,可显著改善患者生活质量,还能显著下调与肿瘤血管生成、侵袭和转移相关的生物标志物水平,且安全性良好。
【Objective】To investigate the efficacy of Anlotinib in the treatment of patients with advanced non-small cell lung cancer(NSCLC)and its influence on quality of life.【Methods】A total of 98 patients with advanced NSCLC treated in our hospital from August 2022 to August 2024 were selected and divided into control group(given conventional chemotherapy)and observation group(given Anlotinib on the basis of conventional chemotherapy)according to different treatment methods,with 49 cases in each group.The clinical efficacy,serum indexes,quality of life and incidence of adverse reactions were compared between the two groups.【Results】The disease control rate and overall response rate of the observation group were higher than those of the control group(P<0.05).After treatment,the levels of vascular endothelial growth factor(VEGF),carbohydrate antigen 125(CA125)and matrix metalloproteinase-9(MMP-9)in the observation group were lower than those in the control group(P<0.05).After treatment,the score of Generic Quality of Life Inventory(GQOLI-74)in the observation group was higher than that in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the observation group and the control group(P>0.05).【Conclusion】Anlotinib combined with conventional chemotherapy has significant efficacy in the treatment of patients with advanced NSCLC,which can significantly improve the quality of life of patients,significantly down-regulate the levels of biomarkers related to tumor angiogenesis,invasion and metastasis,and has good safety.
作者
王潇
陈高瑛
尚艳
WANG Xiao;CHEN Gaoying;SHANG Yan(Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Henan University,Kaifeng Henan 475000)
出处
《医学临床研究》
2025年第6期920-922,926,共4页
Journal of Clinical Research
基金
河南省医学科技攻关计划项目(编号:LHGJ20220648)。
关键词
癌
非小细胞肺
抗肿瘤药
生活质量
治疗结果
Carcinoma,Non-Small-Cell Lung
Antineoplastic Agents
Quality of Life
Treatment Outcome
